LAMICTAL
What it isVoltage-gated sodium-channel blocker with additional calcium and HCN effects; seizures and bipolar maintenance.
Why this oneThe mood stabilizer with the best evidence for preventing bipolar depression, and it is weight-neutral and non-sedating.
What limits itRash risk dictates slow titration; valproate raises exposure, while enzyme inducers and estrogen lower it. Restart cautiously after interruptions.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Epilepsy — adjunctive therapy (partial-onset, PGTC, Lennox-Gastaut) | ≥2 yr; dosing depends on concomitant AED | 25 mg QD (25 mg QOD with valproate; 50 mg QD with inducers) | 225–375 mg/day (100–200 with valproate; 300–500 with inducers) | 700 mg/day (with inducers, no valproate) |
| Epilepsy — conversion to monotherapy (partial-onset) | ≥16 yr | Per adjunctive escalation | 500 mg/day divided BID | 500 mg/day |
| Bipolar I disorder — maintenance | Adults | 25 mg QD (25 mg QOD with valproate; 50 mg QD with inducers) | 200 mg/day (100 with valproate; 400 with inducers) | 200 mg/day |
Titration Increase at 1–2 week intervals per escalation tables; do not exceed recommended initial dose/escalation (rash risk).
Renal Reduced maintenance doses may be effective in significant renal impairment; use with caution.
Hepatic No adjustment for mild; reduce initial/escalation/maintenance ~25% for moderate–severe without ascites and ~50% for severe with ascites.
Pregnancy No consistent increased malformation risk detected; may decrease fetal folate; clearance increases in pregnancy.
Lactation Undefined.
⚠ BOXED WARNING
Cost, est. cash$4–$80/month
Generic entry2006
Legacy pregnancy categoryC
Defining liabilitySerious rash risk is concentrated during rapid titration or re-titration; dizziness and diplopia are common.

Open Lamotrigine in the interactive console ↗

